
Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock?
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $720.06M |
| Gross Profit (TTM) | $608.75M |
| EBITDA | $95.69M |
| Operating Margin | 19.00% |
| Return on Equity | 30.40% |
| Return on Assets | 7.70% |
| Revenue/Share (TTM) | $9.13 |
| Book Value | $4.29 |
| Price-to-Book | 21.27 |
| Price-to-Sales (TTM) | 10.35 |
| EV/Revenue | 9.64 |
| EV/EBITDA | 70.54 |
| Quarterly Earnings Growth (YoY) | -68.40% |
| Quarterly Revenue Growth (YoY) | 53.00% |
| Shares Outstanding | $62.47M |
| Float | $49.58M |
| % Insiders | 4.97% |
| % Institutions | 95.08% |
Volatility is currently expanding

Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock?

Baron Small Cap Fund (the Fund) was up 12.57% (Institutional Shares) in the second quarter, trailing the Russell 2000 Growth Index (the Index) by 13.14%, as the Index was up 25.71%. Shares increased during the quarter as Vertiv reported strong Q1 financial results (adjusted earnings per share increased 83% year-over-year) and increased fiscal year guidance fueled by organic sales growth of around 30%. Planet Fitness, Inc. , the leading high-value, low-cost gym operator, detracted from performance in the second quarter after the company lowered full-year guidance following weaker-than-expected member additions in the first quarter.

Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.

Many people know that seemingly unrelated symptoms can be connected. But in most cases, treating individual symptoms means a separate doctor visit, sometimes to different specialists, before the full picture emerges.

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.

Investors need to pay close attention to HNGE stock based on the movements in the options market lately.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HNGE and any ticker you trade — then tracks every position and per-strategy win rate.